Biomarkers in Multiple Myeloma
Recruiting
N/A
Interventional Study
Hematological Patients
Newly Diagnosed Multiple Myeloma
Chemotherapy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 70 (estimated)
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The association between multiple myeloma (MM) and venous thromboembolism (VTE) is well known. Indeed, the incidence of VTE is increased in patients with newly diagnosed MM and in patients treated by immunomodulatory drugs in combination with glucocorticoids. Moreover, the clinical outcome of MM is supposed to be correlated to the risk of thrombosis. At the biological level, a number of hemostasis …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patient affiliated to a social security regimen or beneficiary of the same
* Signed written informed consent form
* Confirmed diagnosis of de novo multiple myeloma, non-previously treated and requiring treatment.
Exclusion Criteria:
* Pregnant women
* Patient under guardians…
Contacts